TBI conditioning outcomes depend on platform and chemotherapy—not radiation dose alone
This review argues against a universal TBI dose, emphasizing conditioning intensity, chemotherapy backbone, disease biology and patient fitness.
Tag
review
Modern proton breast radiotherapy offers cardiopulmonary sparing but randomized clinical benefit remains pending
Modern proton techniques reduce cardiopulmonary dose and can control skin exposure, while randomized cardiac and cancer-control endpoints remain pending.
Modern radiotherapy shifted the accuracy problem from dose calibration to spatial dose delivery
Modern dosimetry can meet historical accuracy requirements, but tighter geometric precision and particle-specific uncertainties increasingly determine treatment accuracy.
Longer interval to surgery predicted response after preoperative SBRT for luminal breast cancer
Preoperative SBRT produced a pooled 21.4% pathological complete response rate, with irradiation-to-surgery interval strongly associated with response.
Prophylactic dexamethasone reduced pain flare after radiotherapy for bone metastases
Across six randomized studies, prophylactic corticosteroids reduced radiation-induced pain-flare risk by 37%, although regimens and safety reporting varied.
PTCOG review maps emerging roles for particle therapy in gynecologic cancers
Carbon ions show the strongest signal in radioresistant gynecologic tumors, while proton evidence centers on adjuvant treatment and reirradiation.
Esophageal radiosensitization has many molecular targets but little practice-ready clinical evidence
A broad 6R-based review identifies numerous radiosensitization targets, but most remain preclinical and evidence is heavily concentrated in squamous-cell carcinoma.
AI is moving across particle therapy planning but clinical validation remains the bottleneck
AI can automate particle planning, dose prediction, adaptation and quality assurance, but limited data and validation still constrain clinical adoption.
Oligometastatic survivorship is outgrowing traditional oncology follow-up models
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
ESTRO review supports selective CNS reirradiation but highlights cumulative-dose limits
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
Short-course radiotherapy may be a stronger immunotherapy partner in rectal cancer
Recent trials report 40–61% pathologic complete response with short-course radiotherapy plus immunotherapy, but mature comparative outcomes remain unavailable.
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Generative AI is spreading across radiation therapy workflows, but validation remains the bottleneck
A scoping review maps generative AI across imaging, documentation, QA and decision support while emphasizing major safety and governance gaps.
Local control was similar across proton, photon and stereotactic radiotherapy for grade 1 meningioma
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Interim CT shrinkage and FDG-PET uptake predicted head and neck outcomes
Low CT tumour shrinkage strongly predicted poorer locoregional control, while high interim FDG-PET uptake predicted both poorer control and survival.